As the following Her2+ cell lines express same ER, PR and Her2 status but have opposite reactions to the trastuzumab treatment, SK-BR3 (ER-, PR-, Her2+, responsive to trastuzumab) and HCC 1954 (ER-, PR-, Her2+, non-responsive to trastuzumab), we expect that various TNBC cell lines to have various interactions with Tzm-linked micelles depending on their receptors. The gene discussed is ERBB2; the disease is hepatocellular carcinoma.